Allosteric BCR-ABL inhibitors in Philadelphia chromosome-positive acute lymphoblastic leukemia: novel opportunities for drug combinations to overcome resistance (Q43067073)

From Wikidata

Jump to navigation Jump to search

scientific article published in February 2012

Language	Label	Description	Also known as
English	Allosteric BCR-ABL inhibitors in Philadelphia chromosome-positive acute lymphoblastic leukemia: novel opportunities for drug combinations to overcome resistance	scientific article published in February 2012

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

13 November 2017

0 references

Allosteric BCR-ABL inhibitors in Philadelphia chromosome-positive acute lymphoblastic leukemia: novel opportunities for drug combinations to overcome resistance (English)

1 reference

Europe PubMed Central

PMC publication ID

13 November 2017

1 reference

based on heuristic

inferred from title

allosteric inhibitor

1 reference

based on heuristic

inferred from title

lymphoblastic leukemia

1 reference

based on heuristic

inferred from title

Philadelphia chromosome

1 reference

object named as

Philadelphia chromosome

2 August 2024

based on heuristic

inferred from title

Oliver Hantschel

1

1 reference

Europe PubMed Central

PMC publication ID

13 November 2017

publication date

1 February 2012

1 reference

Europe PubMed Central

PMC publication ID

13 November 2017

1 reference

Europe PubMed Central

PMC publication ID

13 November 2017

97

1 reference

Europe PubMed Central

PMC publication ID

13 November 2017

2

1 reference

Europe PubMed Central

PMC publication ID

13 November 2017

157-159

1 reference

Europe PubMed Central

PMC publication ID

13 November 2017

Educational session: managing chronic myeloid leukemia as a chronic disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3269471

25 May 2018

p185(BCR/ABL) has a lower sensitivity than p210(BCR/ABL) to the allosteric inhibitor GNF-2 in Philadelphia chromosome-positive acute lymphatic leukemia.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3269471

25 May 2018

Targeting the SH2-Kinase Interface in Bcr-Abl Inhibits Leukemogenesis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3269471

25 May 2018

Discovery and characterization of a cell-permeable, small-molecule c-Abl kinase activator that binds to the myristoyl binding site

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3269471

25 May 2018

Allosteric interactions between the myristate- and ATP-site of the Abl kinase

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3269471

25 May 2018

Binding or bending: distinction of allosteric Abl kinase agonists from antagonists by an NMR-based conformational assay

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3269471

25 May 2018

Targeting Bcr–Abl by combining allosteric with ATP-binding-site inhibitors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3269471

25 May 2018

Oligomerization inhibition, combined with allosteric inhibition, abrogates the transformation potential of T315I-positive BCR/ABL.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3269471

25 May 2018

Activation of tyrosine kinases by mutation of the gatekeeper threonine

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3269471

25 May 2018

Phosphorylation of the ATP-binding loop directs oncogenicity of drug-resistant BCR-ABL mutants

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3269471

25 May 2018

Kinase domain mutants of Bcr-Abl exhibit altered transformation potency, kinase activity, and substrate utilization, irrespective of sensitivity to imatinib

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3269471

25 May 2018

Organization of the SH3-SH2 unit in active and inactive forms of the c-Abl tyrosine kinase

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3269471

25 May 2018

Allosteric inhibitors of Bcr-abl-dependent cell proliferation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3269471

25 May 2018

Regulation of the c-Abl and Bcr-Abl tyrosine kinases

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3269471

25 May 2018

Structural basis for the autoinhibition of c-Abl tyrosine kinase

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3269471

25 May 2018

A myristoyl/phosphotyrosine switch regulates c-Abl

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3269471

25 May 2018

The molecular biology of chronic myeloid leukemia.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3269471

25 May 2018

Inhibitors of the Abl kinase directed at either the ATP- or myristate-binding site

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3269471

15 August 2018

Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/22298820

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.3324/HAEMATOL.2012.061812

1 reference

Europe PubMed Central

PMC publication ID

13 November 2017

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

13 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

13 November 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43067073&oldid=2218896251"